Natera, Inc. (NASDAQ:NTRA – Get Free Report) CFO Michael Brophy sold 325 shares of Natera stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $399.99, for a total value of $129,996.75. Following the sale, the chief financial officer owned 46,249 shares of the company’s stock, valued at approximately $18,499,137.51. This represents a 0.70% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Michael Burkes Brophy also recently made the following trade(s):
- On Tuesday, November 3rd, Michael Brophy sold 470 shares of Natera stock. The shares were sold at an average price of $391.49, for a total transaction of $184,000.30.
- On Wednesday, October 28th, Michael Brophy sold 1,178 shares of Natera stock. The shares were sold at an average price of $426.46, for a total transaction of $502,369.88.
- On Friday, October 30th, Michael Brophy sold 1,906 shares of Natera stock. The stock was sold at an average price of $425.55, for a total transaction of $811,098.30.
- On Wednesday, October 28th, Michael Brophy sold 1,198 shares of Natera stock. The stock was sold at an average price of $426.34, for a total transaction of $510,755.32.
- On Tuesday, October 27th, Michael Brophy sold 781 shares of Natera stock. The stock was sold at an average price of $406.00, for a total transaction of $317,086.00.
Natera Price Performance
NASDAQ:NTRA opened at $391.03 on Thursday. The firm has a 50 day simple moving average of $380.30 and a 200-day simple moving average of $268.64. The firm has a market cap of $56.36 billion, a PE ratio of -287.52 and a beta of 1.55. Natera, Inc. has a 1-year low of $181.00 and a 1-year high of $437.41.
Natera (NASDAQ:NTRA – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company’s quarterly revenue was up 37.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.74) earnings per share. As a group, sell-side analysts expect that Natera, Inc. will post -1.14 earnings per share for the current fiscal year.
Natera News Summary
Here are the key news stories impacting Natera this week:
- Positive Sentiment: Medicare coverage for Signatera in HCC could improve patient access and support adoption of Natera’s cancer-monitoring tests. The coverage milestone adds to the commercial opportunity for its oncology business. Natera Medicare coverage for Signatera in HCC
- Positive Sentiment: New ESMO oncology evidence was described as broadening the case for Natera’s cancer-testing portfolio, potentially reinforcing the longer-term growth story. ESMO data broaden Natera’s oncology case
- Neutral Sentiment: Natera was expected to report earnings on November 5, making results and management’s outlook a near-term catalyst; the preview article did not provide reported results. Natera earnings preview
- Neutral Sentiment: The reported analyst consensus price target was $394.31, close to the share price cited in the provided market background, suggesting limited implied upside from that target alone. Natera consensus target price
- Neutral Sentiment: CFO Michael Brophy sold 1,178 shares under a pre-arranged Rule 10b5-1 plan and retained 48,480 shares. The scheduled nature and relatively small size of the sale may temper its significance as a signal about management’s outlook. CFO share sale report
Hedge Funds Weigh In On Natera
Several hedge funds and other institutional investors have recently modified their holdings of NTRA. BlackRock Inc. acquired a new stake in Natera during the 2nd quarter worth approximately $2,962,770,000. Arrowstreet Capital Limited Partnership lifted its position in Natera by 1.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,191,732 shares of the medical research company’s stock valued at $238,334,000 after buying an additional 11,793 shares in the last quarter. Maverick Capital Ltd. lifted its position in Natera by 24.1% during the first quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company’s stock valued at $234,315,000 after buying an additional 227,605 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Natera by 10.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 833,376 shares of the medical research company’s stock valued at $226,220,000 after buying an additional 80,440 shares in the last quarter. Finally, Bank of America Corp DE purchased a new stake in Natera during the second quarter worth approximately $199,960,000. 99.90% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
NTRA has been the subject of a number of recent analyst reports. Zacks Research downgraded Natera from a “hold” rating to a “strong sell” rating in a research report on Friday, October 16th. TD Cowen increased their target price on Natera from $340.00 to $480.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. Roth Capital began coverage on Natera in a research note on Thursday, October 22nd. They issued a “buy” rating and a $475.00 price target on the stock. Piper Sandler upped their price objective on shares of Natera from $249.00 to $363.50 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Finally, Wells Fargo & Company upped their price objective on shares of Natera from $220.00 to $284.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $394.31.
Check Out Our Latest Analysis on NTRA
Natera Company Profile
Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.
In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.
Featured Stories
- Five stocks we like better than Natera
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
